인유두종바이러스 백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Human Papillomavirus Vaccine Market size is expected to reach USD 21.09 Billion in 2034 from USD 9.66 Billion (2025) growing at a CAGR of 9.06% during 2026-2034.

The global human papillomavirus vaccine market is positioned for accelerated growth as immunization programs gain prominence across both developed and emerging economies. Expanding government-led initiatives, rising awareness of HPV-related cancers, and increasing accessibility of vaccines through public-private partnerships are driving adoption rates. Biotechnology advances, including thermostable formulations and next-generation adjuvant systems, are addressing cold-chain limitations and enhancing efficacy, making vaccination campaigns more effective in resource-constrained regions.

Continuous research into broader-spectrum HPV vaccines is reshaping the competitive landscape. The push for multivalent formulations that cover an expanded range of oncogenic strains will significantly boost the long-term impact of vaccination strategies. Meanwhile, integration of HPV vaccines into national immunization schedules, coupled with digital health platforms for monitoring and compliance, is reinforcing systemic adoption. Additionally, pharmaceutical manufacturers are prioritizing scalable production platforms such as recombinant DNA technologies and cell-based systems, allowing for cost reduction and expanded supply availability.

In the future, collaborations between biopharma companies, diagnostic firms, and public health agencies will drive a holistic approach to HPV prevention. The growing convergence of vaccines with AI-driven epidemiological modeling, precision public health frameworks, and global awareness campaigns will intensify uptake. With rising emphasis on preventive healthcare, equitable access, and personalized immunization schedules, the HPV vaccine market will continue to expand as a cornerstone of global cancer control strategies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Bivalent
• Quadrivalent
• Nonavalent

By Disease

• Cervical Cancer
• Vaginal and Vulvar Cancers
• Anal Cancer
• Oropharyngeal (Head and Neck) Cancers
• Genital Warts

By Distribution Channel

• Hospitals and Retail Pharmacies
• Government Suppliers
• Others

COMPANIES PROFILED

• Merck Co Inc, GlaxoSmithKline plc GSK, Serum Institute of India Pvt Ltd, Sanofi Pasteur SA, Pfizer Inc, Inovio Pharmaceuticals Inc, Walvax Biotechnology Co Ltd, Bharat Biotech International Ltd, Johnson Johnson Services Inc, Moderna Inc, Gilead Sciences Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Bivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Quadrivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Nonavalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY DISEASE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Disease
• 5.2. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Vaginal and Vulvar Cancers Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Anal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.5. Oropharyngeal (Head and Neck) Cancers Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.6. Genital Warts Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospitals and Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Government Suppliers Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Type
  • 7.2.2 By Disease
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Type
  • 7.3.2 By Disease
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Type
  • 7.4.2 By Disease
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Type
  • 7.5.2 By Disease
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Type
  • 7.6.2 By Disease
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HUMAN PAPILLOMAVIRUS VACCINE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Merck & Co. Inc
  • 9.2.2 GlaxoSmithKline Plc (GSK)
  • 9.2.3 Serum Institute Of India Pvt. Ltd
  • 9.2.4 Sanofi Pasteur SA
  • 9.2.5 Pfizer Inc
  • 9.2.6 Inovio Pharmaceuticals Inc
  • 9.2.7 Walvax Biotechnology Co. Ltd
  • 9.2.8 Bharat Biotech International Ltd
  • 9.2.9 Johnson & Johnson Services Inc
  • 9.2.10 Moderna Inc
  • 9.2.11 Gilead Sciences Inc